Newsletter Signup | Join Community
Checkpoint PD-1 inhibitors and Sacituzumab Govitecan (IMMU-132) promising treatment for triple negative breast cancer
IMpassion130 clinical trial of Tecentriq improves outcomes of Triple Negative Breast Cancer and leads to FDA approval
New England Journal of Medicine study updates promising activity of Sacituzumab treatment for triple neg breast cancer.
Stay Current With Triple-Negative Breast Cancer Treatment Advances & Connect with Others
Dr. Bhuvaneswari Ramaswamy of the OSU Arthur G. James Cancer Hospital answers frequently asked questions about TNBC
Iniparib Promising in Metastatic Triple-negative Breast Cancer
Obesity Linked with Triple-Negative Breast Cancer
Erbitux May Increase Response Rates in Metastatic Triple-Negative Breast Cancer.
Triple Negative Breast Cancer Linked with Higher Rate of Distant Metastases.
Triple Negative Breast Cancer Foundation
Interesting data published this week show HDC appears to benefit TNBC: https://mavendoctors…